• DiaMedica Therapeutics rescheduled its virtual fetal growth restriction webinar to November 24, 2026, from October 23, 2026.
• The event starts at 8 a.m. EST and will cover DM199 as a potential treatment for fetal growth restriction.
• Presentations will include interim safety and clinical findings from the first six participants across two Phase 2 early-onset fetal growth restriction cohorts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DiaMedica Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610190800BIZWIRE_USPR_____20261019_BW862168) on October 19, 2026, and is solely responsible for the information contained therein.